5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now

Shares of Alnylam (NASDAQ: ALNY) recently dipped after Intellia (NASDAQ: NTLA) stole the spotlight with trial results for a revolutionary new gene therapy that could compete with Onpattro, Alnylam's top drug at the moment. It does look like Onpattro could be in for some serious competition, but that doesn't mean you should avoid shares of the biotech pioneer. 

Alnylam's drug development engine is spewing out new drugs that interfere with the production of troublesome proteins so quickly that potential competition from Intellia probably isn't going to be an issue.  

Image source: Getty Images.

Continue reading

Source Fool.com